Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Diabetes UK

- PMLiVE

NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

- PMLiVE

King’s College London and 11 London collaborate on health psychology

We’re delighted to announce that we are working in partnership with the Health Psychology department at King's College London. Professor Rona Moss-Morris is working with the agency on a shared...

11 London

- PMLiVE

New genetic risk tool could predict multiple sclerosis in young adults much earlier

Approximately 2.8 million people worldwide are affected by the disabling neurological disease

- PMLiVE

Incisionless device to transform diabetes, liver disease and severe obesity treatment

ForePass replicates common invasive metabolic surgeries without making any incisions

- PMLiVE

Two KCL research projects awarded £4.8m to help find cure for type 1 diabetes

The Type 1 Diabetes Grand Challenge has awarded six research projects grants totalling £13m

- PMLiVE

International study reveals how to measure long COVID severity and impact

A set of 12 recommendations were established for scientific and clinical communities

- PMLiVE

New research highlights mental health support gap for autoimmune disease patients

More than 1,800 patients with SARDs were surveyed for neurological and psychiatric symptoms

- PMLiVE

Eli Lilly to acquire Sigilon in deal worth over $300m

The companies have been working together since 2018 on cell therapies for type 1 diabetes

- PMLiVE

FDA approves CellTrans’ Lantidra as first cellular therapy to treat type 1 diabetes

The therapy is indicated for use in patients who are unable to meet their target blood glucose levels

- PMLiVE

Tiziana to develop intranasal foralumab for type 1 diabetes

Approximately 4.7 million people in the UK are currently living with diabetes

- PMLiVE

Sanofi to acquire Provention Bio in deal worth $2.9bn

The merger includes recently-approved type 1 diabetes prevention therapy Tzield

- PMLiVE

Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval

Tidepool Loop is the first app of its kind to receive clearance in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links